Skip Navigation

European Journal of Heart Failure 2004 6(6):787-791; doi:10.1016/j.ejheart.2004.09.001
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cleland, J. G.F.
Right arrow Articles by Coletta, A. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cleland, J. G.F.
Right arrow Articles by Coletta, A. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 European Society of Cardiology

Clinical trials update from the European Society of Cardiology: SENIORS, ACES, PROVE-IT, ACTION, and the HF-ACTION trial

John G.F. Clelanda, P. Huan Loha, Nick Freemantleb, Andrew L. Clarka and Alison P. Colettaa,*

a Department of Cardiology, University of Hull, Castle Hill Hospital Cottingham, Kingston-upon-Hull, HU16 5JQ, UK
b Department of Primary Care and General Practice, University of Birmingham Edgbaston, Birmingham B15 2TT, UK

* Corresponding author. Tel.: +44 1482 624086; fax: +44 1482 624085.. E-mail address: a.p.coletta{at}hull.ac.uk


  Abstract

This article provides information and a commentary on landmark trials presented at the European Society of Cardiology Congress in August 2004, relevant to the pathophysiology, prevention or treatment of heart failure. The SENIORS trial suggests that nebivolol is well tolerated and effective in older patients with heart failure, even if left ventricular systolic function is not markedly depressed. However, patients aged >75 years appeared to gain less benefit. Further data on the effects of nebivolol on symptoms and quality of life are awaited. Two new trials of long-term antibiotic prophylaxis after myocardial infarction (ACES and PROVE-IT) showed no benefit. The ACTION trial showed no reduction in serious cardiovascular events with nifedipine GITS in patients with chronic stable angina, despite a substantial reduction in blood pressure. The HF-ACTION trial announced that the first 700 patients of a projected 3000 had been randomised to either an exercise program or encouragement to exercise but without a formal program. The primary outcome measure is death or hospitalisation for any reason.

Key Words: SENIORS • ACES • PROVE-IT • ACTION • HF-ACTION trial

Received September 2, 2004; Accepted September 8, 2004


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur J Heart FailHome page
R. Fraga, F. G. Franco, F. Roveda, L. N.J. de Matos, A. M.F.W. Braga, M. U.P.B. Rondon, D. R. Rotta, P. C. Brum, A. C.P. Barretto, H. R. Middlekauff, et al.
Exercise training reduces sympathetic nerve activity in heart failure patients treated with carvedilol
Eur J Heart Fail, June 1, 2007; 9(6-7): 630 - 636.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
F. Cao, A. Castrillo, P. Tontonoz, F. Re, and G. I. Byrne
Chlamydia pneumoniae-Induced Macrophage Foam Cell Formation Is Mediated by Toll-Like Receptor 2
Infect. Immun., February 1, 2007; 75(2): 753 - 759.
[Abstract] [Full Text] [PDF]

Home page
 ICVTSHome page
M. Berman, D. Hasdai, E. Raanani, G. P. Georghiou, L. Kapustin, Y. Chepurko, B. A. Vidne, and E. Hochhauser
Ex-vivo effect of roxithromycin on human and rat arterial vasoactivity
Interactive CardioVascular and Thoracic Surgery, June 1, 2005; 4(3): 232 - 237.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
J G F Cleland, A Torabi, and N K Khan
Epidemiology and management of heart failure and left ventricular systolic dysfunction in the aftermath of a myocardial infarction
Heart, May 1, 2005; 91(suppl_2): ii7 - ii13.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.